Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 7.4% in the afternoon session after the ...

Complex regions of the human genome remained uncharted, even after researchers sequenced the genome in its entirety. That is, ...

History, Year 8 (v8.4) The way Polynesian societies used environmental resources (sustainably and unsustainably), including ...

New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencingMENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a ...

The global clinical next-generation sequencing (NGS) market, valued at USD 6.2 billion in 2024, is expected to reach USD 15.2 billion by 2032 with a ...

In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.39, marking a -6.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of ...

Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

Researchers have decoded the chromosome-level genome of Houttuynia cordata, an important East Asian medicinal plant known for its strong flavor and ...